SOLICITATION NOTICE
J -- Notice of Intent to Sole Source BD FACScanto Flow Cytometer with FACSLloader Maintenance and Support Services
- Notice Date
- 3/25/2020 11:33:48 AM
- Notice Type
- Presolicitation
- Contracting Office
- FDA OFFICE OF ACQ GRANT SVCS ROCKVILLE MD 20857 USA
- ZIP Code
- 20857
- Solicitation Number
- 1221782
- Response Due
- 4/1/2020 2:30:00 AM
- Archive Date
- 04/16/2020
- Point of Contact
- Nikola Zuber, Phone: 3017969671
- E-Mail Address
-
Nikola.Zuber@fda.hhs.gov
(Nikola.Zuber@fda.hhs.gov)
- Description
- The Food and Drug Administration intends to make a sole source award for an BD FACSCanto Flow Cytometer with FACSLoader maintenance and support services. The award will be made to: BD Biosciences 2350 Qume Dr San Jose CA 95131 In accordance with FAR 6.302-1, FAR 13.106(b) and FAR 5.203, Only one responsible source and no other supplies or services will satisfy agency requirements. The FDA�s FACSCanto 4/3/3 Flow Cytometer is a shared resource for members of the CBER and CDER research and review centers and used by a broad range of FDA investigators for many applications in basic and applied research. As a shared resource for many programs within the FDA, reliability and optimal performance is essential; Downtime is catastrophic for many assays and scientific responsibilities require the minimization of service-related issues. BD Biosciences is the sole source of BD FACSCanto Flow Cytometer maintenance and support services. BD Biosciences is the developer and manufacturer of this equipment and possess the proprietary information required to service this instrument. BD Biosciences provides technology and software updates unique to their flow cytometry research and development; This is not available through any other sources. BD Biosciences updates are specific to their instrumentation and only BD possesses the proprietary information necessary to build, integrate, troubleshoot, and distribute the updates. The proprietary information and software updates are considered a essential requirement for this acquisition, therefore in is in the best interest of the government to plan an award to BD Biosciences. This notice of intent is not a request for competitive quotes. However, all responsible sources may submit a capability statement within seven (7) days after the publication of this synopsis which shall be considered by the agency. Responses received after 7 days or without the required information may not be considered. For information concerning this acquisition contact: Nikola Zuber Contract Specialist Nikola.Zuber@fda.hhs.gov (301) 796 - 9671 A determination by the Government not to compete because of information received is solely within the discretion of the Government. Information received will normally be considered solely for determining whether to conduct a competitive procurement.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/179e10c031db428c9cf56979dad0645c/view)
- Record
- SN05599794-F 20200327/200325230140 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |